Xuanzhu Biopharmaceutical (HKG:2575) said it has filed an application with the China Securities Regulatory Commission to implement Hong Kong shares' full circulation, according to a Monday Hong Kong bourse filing.
Shares of the biopharmaceutical firm were down nearly 1% in Tuesday afternoon trade.
The plan involves converting 357.2 million unlisted shares into the same number of Hong Kong shares on a one-for-one basis.
The converted shares will be listed and traded in Hong Kong once all necessary regulatory approvals have been obtained, including approval from the bourse for the conversion and listing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments